Recursion Pharmaceuticals (RXRX) Income from Non-Controlling Interests (2020 - 2021)
Recursion Pharmaceuticals' (RXRX) quarterly Income from Non-Controlling Interests came in at $43.4 million in Q2 2021, up 129.11% YoY from $18.9 million in Q2 2020, and up 241.29% on a QoQ basis from -$30.7 million in Q1 2021.
Powered by 
Analysis
Recursion Pharmaceuticals (RXRX) Income from Non-Controlling Interests (2020 - 2021) Analysis & Trends
Recursion Pharmaceuticals (RXRX) has 2 years of Income from Non-Controlling Interests data on file, last reported at $43.4 million in Q2 2021.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Inc. Minority (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.62 Bn | 131.77 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 85.73 Bn | 77.73 Bn | 3.93 Bn | - |
| 3 | Argenx Se | 63.53 Bn | 58.35 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.23 Bn | 53.09 Bn | 52.00 Mn | - |
| 5 | Revolution Medicines | 44.05 Bn | 44.05 Bn | - | - |
| 6 | BeOne Medicines | 40.03 Bn | 34.93 Bn | 1.53 Bn | - |
| 7 | Alnylam Pharmaceuticals | 35.50 Bn | 32.19 Bn | 992.69 Mn | - |
| 8 | Royalty Pharma | 28.52 Bn | 27.68 Bn | - | 63.60 Mn |
| 9 | Insmed | 27.46 Bn | 26.30 Bn | 358.27 Mn | - |
| 10 | Recursion Pharmaceuticals | 1.92 Bn | 1.37 Bn | -3.82 Mn | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2021 | 43.40 Mn |
| Mar 31, 2021 | -30.72 Mn |
| Jun 30, 2020 | 18.94 Mn |
| Mar 31, 2020 | -18.42 Mn |